Skip to search formSkip to main content

everolimus 5 MG Oral Tablet [Afinitor]

Known as: Afinitor 5 MG Oral Tablet 
 
National Institutes of Health

Related topics

Related topics

8 relations
Butylated HydroxytolueneCrospovidoneLactose MonohydrateMagnesium stearate
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis in vitro and in a mouse model.
Infection with the larval stage (metacestode) of the fox tapeworm Echinococcus multilocularis leads to a primary hepatic disease… Expand
Is this relevant?
2015
2015
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
BACKGROUND Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2014
2014
Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women – Ergebnisse der ersten Interimsanalyse der nicht-interventionellen Studie BRAWO
 
Is this relevant?
2013
2013
BRAWO – Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women
 
Is this relevant?
Review
2012
Review
2012
Pancreatic Neuroendocrine and Carcinoid Tumors: What’s New, What’s Old, and What’s Different?
Well-differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and pancreatic NETs (panNETs). Recently, two… Expand
  • figure 1
Is this relevant?
Review
2011
Review
2011
Everolimus for the treatment of advanced renal cell carcinoma.
INTRODUCTION The efficacy of sequential everolimus (RAD001, Afinitor®), an orally administered inhibitor of mammalian target of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
1167 POSTER Comparison of the Impact of the Targeted Therapy Everolimus (Afinitor®) and the Chemotherapy 5-FU on Cognitive Functions and Cerebral Plasticity in an Animal Model
 
Is this relevant?
Review
2009
Review
2009
Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms
ZusammenfassungDie letzten 5 Jahre waren durch grundlegende Veränderungen in der Systemtherapie des metastasierten… Expand
Is this relevant?